Sales 2024 * | 240M 327M | Sales 2025 * | 299M 408M | Capitalization | 2.36B 3.22B |
---|---|---|---|---|---|
Net income 2024 * | 4M 5.45M | Net income 2025 * | 24M 32.72M | EV / Sales 2024 * | 9.82 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 7.88 x |
P/E ratio 2024 * |
560
x | P/E ratio 2025 * |
103
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.07% |
Latest transcript on Aastrom Biosciences Inc
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 60 | 13-02-28 | |
Joseph Mara
DFI | Director of Finance/CFO | 49 | 21-01-24 |
Michael Halpin
COO | Chief Operating Officer | 62 | 17-04-09 |
Members of the board | Title | Age | Since |
---|---|---|---|
Paul Wotton
BRD | Director/Board Member | 63 | 15-01-05 |
Kevin McLaughlin
BRD | Director/Board Member | 67 | 15-01-05 |
Robert Zerbe
CHM | Chairman | 73 | 06-01-15 |
1st Jan change | Capi. | |
---|---|---|
-1.26% | 89.46B | |
+2.76% | 40.74B | |
-12.32% | 33.03B | |
+54.94% | 24.68B | |
-17.39% | 15.12B | |
-9.14% | 12.81B | |
-10.48% | 11.79B | |
-42.45% | 11.64B | |
+7.72% | 8.9B |